Understanding UGT2B11: A Potential Drug Target or Biomarker (G10720)

Target Name: UGT2B11

NCBI ID: G10720

UGT2B11

Understanding UGT2B11: A Potential Drug Target or Biomarker

UGT2B11 (UDP-glucuronosyltransferase 2B11) is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and gastrointestinal tract. It plays a critical role in the detoxification and metabolism of drugs, as well as other substances that are harmful to the body.

UGT2B11 is a member of the UGT family of enzymes, which are known as the major transport proteins. These enzymes are responsible for carrying out the process of glucose transport, which is the transfer of glucose from the food we eat to the bloodstream. UGT2B11 is specific to the transport of glucose to the liver, where it is metabolized and excreted.

One of the unique features of UGT2B11 is its ability to transfer glucose to the liver using a specific mode of transport, known as the N-terminal translocation mode. This mode allows UGT2B11 to efficiently transport glucose across the blood-brain barrier, which is a barrier that separates the brain from the bloodstream. This is important for the brain, as it is the primary source of glucose for the body's cells, including the brain.

UGT2B11 has been shown to play a critical role in the metabolism of many drugs that are used to treat a wide range of medical conditions. For example, some studies have suggested that UGT2B11 may be involved in the metabolism of the drug cisapride, which is used to treat the symptoms of rabies. Other studies have suggested that UGT2B11 may be involved in the metabolism of the drug metformin, which is used to treat type 2 diabetes.

In addition to its role in drug metabolism, UGT2B11 is also thought to be involved in the detoxification of other substances that are harmful to the body. For example, UGT2B11 has been shown to be involved in the detoxification of the chemical acrylamide, which is a potential carcinogen.

Despite its many important functions, UGT2B11 is not yet a well-studied protein. There are only a few studies that have investigated its role in the body, and more research is needed to fully understand its mechanisms of action and potential as a drug target or biomarker.

In conclusion, UGT2B11 is a protein that is expressed in various tissues throughout the body and plays a critical role in the detoxification and metabolism of drugs, as well as other substances that are harmful to the body. While more research is needed to fully understand its mechanisms of action, it is potential drug target or biomarker that could be targeted by scientists in the future.

Protein Name: UDP Glucuronosyltransferase Family 2 Member B11

Functions: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds

The "UGT2B11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT2B11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets